
Sign up to save your podcasts
Or


A large, expanded-cohort pooled analysis of neoadjuvant immunotherapy for patients with resectable Stage III melanoma has reported very high rates of durable survival. The findings from the world's biggest center of expertise in melanoma were announced at ESMO Congress 2024.
The study included patients from clinical trials and real-world studies who had pure immune checkpoint inhibitor neoadjuvant therapy, or combinations including BRAF/MEK targeted therapy. After giving her talk in Barcelona, lead investigator Georgina Long, AO, PhD, MBBS, FRACP, Professor and Co-Medical Director at the Melanoma Institute Australia, University of Sydney, gave Oncology Times reporter Peter Goodwin the details.
Drug resistance can be delayed and treatment outcomes predicted in patients with ovarian cancer with the help of relatively low-cost molecular precision management techniques using liquid biopsies. These are being developed by a team at the University of California in Los Angeles (UCLA) led by Jian Yu Rao, MD, Vice Chair of Diagnostic Technology Innovation at UCLA, where he is also Chief of Cytopathology and Director of International Telepathology.
At the 2024 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) held in Xiamen, China, Rao gave Oncology Times reporter Peter Goodwin details of the molecular methods he had just outlined to the conference.
Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the ESMO 2024 Congress. Rebecca Dent, MD, Scientific Chair of the meeting, as well as Medical Oncologist and Deputy Chief Executive Officer at the National Cancer Center in Singapore (with a special interest in all aspects of triple-negative breast cancer), shared the key areas of progress covered by the meeting.
The escalating danger of cardiac toxicity posed by a range of increasingly effective anti-cancer therapies is insufficiently understood, according to the head of a world center of excellence for the study of cardio-oncology in northern China.
At a special session devoted to cardio-oncology held at the Chinese Society of Clinical Oncology (CSCO) 2024 Annual Meeting, the challenges of cardio-oncology were examined by a committee of experts with reference to the CSCO Clinical Practice Guide for Tumor Cardiology.
Among the speakers was cardiologist Yun-Long Xia, MD, PhD, FESC, FHRS, Head of Cardiovascular Medicine at Dalian Medical University in China. Afterward, he talked about their conclusions with Oncology Times reporter Peter Goodwin.
Details of the expanding range of cell therapies beyond hematologic malignancy were reported at the 2024 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) by Oliver Dorigo, MD, PhD, Director of the Division of Gynecologic Oncology at the Stanford Women's Cancer Center in Stanford University.
After his talk at CSCO, Dorigo told Oncology Times reporter Peter Goodwin about the promise cell therapies held for improving outcomes in ovarian cancer and other solid tumors, as well as the benefit of the exchange of ideas flowing between China, U.S., and other global players in this young science.
An assessment of progress with antibody-drug conjugates (ADCs) for the treatment of HER2-dependent metastatic breast cancer was given at the 2024 Chinese Society of Clinical Oncology (CSCO) Annual Meeting. The President-Elect of the European Society for Medical Oncology (ESMO), Giuseppe Curigliano, MD, PhD, Director of the Early Drug Development for Innovative Therapies Division at the European Institute of Oncology and the University of Milano in Italy, told Oncology Times reporter Peter Goodwin about the broadening scope of ADCs in breast cancer and his reasons for encouraging ESMO and CSCO to continue to expand their co-operation.
At the opening session of the Chinese Society of Clinical Oncology (CSCO) 2024 Annual Meeting, attended by nearly 30,000 cancer specialists, Oncology Times reporter Peter Goodwin asked the President of CSCO, Xu Ruihua, MD, PhD, Professor and President of Sun Yat-sen University Cancer Center in Guangzhou, China, to talk about some of the ways that progress in cancer treatments had been made more productive by co-operation between Chinese and Western centers of oncology excellence.
Important findings about the benefit of neoadjuvant therapies, especially those involving checkpoint inhibition, have been reported at the 2024 Annual meeting of the European Society for Medical Oncology, ESMO. The Scientific Chair of the meeting, Rebecca Dent MD, Deputy Chief Executive Officer of the National Cancer Center in Singapore, told Oncology Times reporter Peter Goodwin about some of the key areas of progress covered by the meeting that she was most excited about.
A large international cohort study has found that women testing positive for the BRCA mutation who chose to breastfeed their babies after treatment for their breast cancer faced no additional risk to their cancer outcomes.
OncTimesTalk correspondent Peter Goodwin talked with Eva Blondeaux, MD, Medical Oncologist in the Epidemiology Unit at the IRCCS Ospedale Policlinico San Martino, Genoa, Italy, and the author of the study, after her presentation of the new data at the ESMO 2024 Congress.
Women who chose to interrupt their endocrine therapy after their breast cancer surgery to have a baby faced no additional cancer risk, according to data from the POSITIVE study reported at the ESMO Congress 2024.
In Barcelona, OncTimesTalk reporter Peter Goodwin met up with Fedro Peccatori, MD, PhD, Director of the Fertility and Procreation Unit in the Division of Gynecologic Oncology at the European Institute of Oncology, Milan, Italy, after he reported his group's findings. "Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial," Peccatori noted.
From the publisher's feed